Quarterly report pursuant to Section 13 or 15(d)

Impact of COVID-19 (Details)

v3.20.2
Impact of COVID-19 (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
test
Jun. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Unusual or Infrequent Item, or Both [Line Items]          
Total test volume (as a percent) 63.00%        
Total revenues $ 428,064   $ 228,772 $ 940,739 $ 677,592
Transfer of intellectual property and other          
Unusual or Infrequent Item, or Both [Line Items]          
Total revenues 16,864   $ 21,472 47,297 $ 58,961
CMS Accelerated and Advanced Payment Program, COVID-19          
Unusual or Infrequent Item, or Both [Line Items]          
Proceeds from issuance of debt   $ 14,000      
Distribution to Healthcare Providers, COVID-19          
Unusual or Infrequent Item, or Both [Line Items]          
Proceeds from issuance of debt $ 10,000     16,200  
Distribution to Healthcare Providers, COVID-19 | Transfer of intellectual property and other          
Unusual or Infrequent Item, or Both [Line Items]          
Total revenues       $ 16,200  
Diagnostics          
Unusual or Infrequent Item, or Both [Line Items]          
Change in testing volume (as a percent) (9.10%)        
Serology Antibody Test          
Unusual or Infrequent Item, or Both [Line Items]          
Number of tests performed | test 300,000        
Tests performed per day | test 400,000        
Diagnostic Molecular Test          
Unusual or Infrequent Item, or Both [Line Items]          
Number of tests performed | test 3,500,000        
Tests performed per day | test 70,000